As filed with the Securities and Exchange Commission on April 5, 2024. Registration No. 333-278073 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________________ Longeveron Inc. (Exact name of registrant as specified in its charter) __________________________________________ | Delaware | 2834 | 47-2174146 | | --- | --- | --- | | (S ...

Registration No. 333-278073 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Amendment No. 1 to As filed with the Securities and Exchange Commission on April 3, 2024. FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________________ Longeveron Inc. (Exact name of registrant as specified in its charter) __________________________________________ | Delaware | 2834 | 47-2174146 | | --- | --- | --- | | (S ...

As filed with the Securities and Exchange Commission on March 19, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________________ Longeveron Inc. (Exact name of registrant as specified in its charter) __________________________________________ | Delaware | 2834 | 47-2174146 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Mike Moyer – Managing Director Wa'el Hashad – Chie Executive Officer Nataliya Agafonova – Chief Medical Officer Lisa Locklear – Chief Financial Officer Conference Call Participants Dipesh Patel – H.C. Wainwright Michael Okunewitch – Maxim Group Brad Sorensen – Zacks Research Operator Ladies and gentlemen, good afternoon, and welcome to the Longeveron Fourth Quarter and Full Year 2023 Earnings Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40060 LONGEVERON INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organi ...

As filed with the Securities and Exchange Commission on January 29, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Longeveron Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Delaware 2834 47-2174146 (I.R.S. Employer Identification Number) 1951 NW 7 Avenue, Suite 520 Miami, Florida ...

As filed with the Securities and Exchange Commission on November 15, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 | Longeveron Inc. | | --- | | (Exact name of registrant as specified in its charter) | (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Delaware 2834 47-2174146 1951 NW 7 Avenue, Suite 520 Miami, Florida 33136 (305) 909-0840 ...

Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Conference Call November 10, 2023 8:30 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa’el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua M. Hare - Co-Founder, Chief Science Officer and Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief que ...

Lomecel-B™ Clinical Programs - Lomecel-B™ is in Phase 2 trials for Hypoplastic Left Heart Syndrome (HLHS), Aging-Related Frailty, and Alzheimer's Disease [14, 20] - A Phase 2 trial in Japan for Aging-Related Frailty is ongoing [12, 24] - Enrollment is completed in a Phase 2a trial for Alzheimer's Disease, with topline data anticipated by October 2023 [20, 90] - ELPIS II, an ongoing Phase 2 trial of Lomecel-B™ in HLHS, aims to improve Right Ventricular Ejection Fraction (RVEF) [71, 72] Aging-Related Frailty - A Phase 2b study (N=143) explored the dose response of Lomecel-B™ in aging-related frailty [59] - The study showed a statistically significant dose response at 180 days, with p<0.05 and p<0.01 versus placebo [62] - The study included treatment groups with 25 million, 50 million, 100 million, and 200 million Lomecel-B™ cells [61, 74] Alzheimer's Disease - A Phase 1b randomized, placebo-controlled trial (N=33) of Lomecel-B™ in Alzheimer's Disease showed a statistically significant improvement in cognition as measured by MMSE scores in the low-dose (20 million cells) group compared to placebo [85, 98] - The Phase 1b trial included patients with MMSE scores of 18-24 [86] - The Phase 2a Alzheimer's Disease study design is ongoing with 48 patients [89, 123] Hypoplastic Left Heart Syndrome (HLHS) - In SVR historically matched controls, 5-year mortality was ~20% [49] - Positive ELPIS 1 (Phase 1b) Trial Results (N=10) showed no transplants required in the 10 patients during the one year of the study duration [33]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) | Delaware | 47-2174146 | | --- | --- | | (State or Other ...